Zenas BioPharma (USA), LLC
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-34
RECRUITING2
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO20%
Delay Index: of 5 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.4 months). See all sponsors →
Open Zenas BioPharma (USA), LLC on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Obexelimab NCT06564311 |
P2 | Active, not recruiting | Relapsing Multiple Sclerosis | 93 | 2025-08-28 |
| INDIGO NCT05662241 |
P3 | Active, not recruiting | IgG4 Related Disease | 194 | 2025-11-13 |
| Obexelimab NCT05786573 |
P3 | Active, not recruiting | Warm Autoimmune Hemolytic Anemia | 134 | 2026-06-30 (-6 mo) |
| SunStone NCT06559163 |
P2 | Active, not recruiting | Systemic Lupus Erythematosus | 190 | 2026-09-23 (+11 mo) |
| Orelabrutinib NCT07067463 |
P3 | Recruiting | Multiple Sclerosis (MS) Primary Progressive | 705 | 2030-06 |
| Orelabrutinib NCT07299019 |
P3 | Recruiting | Secondary Progressive Multiple Sclerosis | 990 | 2030-06 |